Virometix closes Extension Financing Round and appoints Harry Welten as new independent Board Member
Virometix today announced that it has raised CHF 1.2 million from new shareholders in an extension to its recent Series A financing round. The additional funds will be used to further speed up development of its vaccine candidates for RSV and cancer immunotherapy. Furthermore, the company announced the appointment of Harry Welten, MBA as new independent member of its Board of Directors.